US90400D1081

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 16:30 ET  | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical…

13 hours ago

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

July 11, 2025 16:30 ET  | Source: Ultragenyx Pharmaceutical Inc. Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls…

1 week ago